New hope for advanced cancer: combo therapy trial launches

NCT ID NCT06953089

Recruiting now Disease control Sponsor: DualityBio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health and have at least one measurable tumor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer cervical cancer colorectal cancer head and neck squamous cell carcinoma hepatocellular carcinoma melanoma metastatic prostate carcinoma non-small cell lung carcinoma ovarian cancer ovarian carcinoma pancreatic ductal adenocarcinoma refractory malignant neoplasm Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

AUS04-0
RECRUITING

Birtinya, Queensland, 4575, Australia
AUS05-0
RECRUITING

Adelaide, South Australia, 5000, Australia
AUS06-0
RECRUITING

Benowa, Queensland, 4217, Australia
AUS07-0
RECRUITING

North Sydney, New South Wales, 2060, Australia
CHN01-0
RECRUITING

Shanghai, Shanghai Municipality, 200120, China
CHN02-0
RECRUITING

Beijing, Beijing Municipality, 100021, China
CHN04-0
RECRUITING

Hubei, Hubei, 430014, China
CHN04-0
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
CHN06-0
RECRUITING

Henan, Henan, 450008, China
CHN11-0
RECRUITING

Changsha, Hunan, 410013, China
CHN12-0
RECRUITING

Xinxiang, Henan, 453100, China
CHN13-0
RECRUITING

Beijing, Beijing Municipality, 100032, China
CHN16-0
RECRUITING

Xuzhou, Jiangsu, 221000, China
CHN17-0
RECRUITING

Dongguan, Guangdong, 523000, China
CHN23-0
RECRUITING

Beijing, Beijing Municipality, 100142, China
CHN24-0
RECRUITING

Chengdu, Sichuan, 610041, China
CHN25-0
RECRUITING

Xi'an, Shaanxi, 710061, China
CHN26-0
RECRUITING

Wuhan, Hubei, 00000, China
CHN34-0
RECRUITING

Wuhan, Hubei, 430079, China
CHN35-0
RECRUITING

Shenyang, Liaoning, 110042, China
TWN01-0
RECRUITING

Taipei, Taipei, 0, Taiwan
TWN02-0
RECRUITING

Taipei, Taipei, 23561, Taiwan
USA01-0
RECRUITING

Wheat Ridge, Colorado, 80033, United States
USA03-0
RECRUITING

Charleston, South Carolina, 29425, United States
USA04-0
RECRUITING

New York, New York, 10032, United States
USA05-0
RECRUITING

Virginia Beach, Virginia, 22031, United States
USA06-0
RECRUITING

Los Angeles, California, 90025, United States
USA07-0
RECRUITING

Spokane, Washington, 99208, United States
USA08-0
RECRUITING

Florida City, Florida, 99208, United States
USA09-0
RECRUITING

Puyallup, Washington, 98373, United States
USA10-0
RECRUITING

Atlanta, Georgia, 30318, United States
USA11-0
RECRUITING

Bethesda, Maryland, 20817, United States
USA12-0
RECRUITING

Houston, Texas, 77030, United States
USA13-0
RECRUITING

Anderson, Texas, 46011, United States
USA14-0
RECRUITING

Lincoln, Nebraska, 68506, United States
USA15-0
RECRUITING

Portland, Oregon, 97239, United States
USA16-0
RECRUITING

Los Angeles, California, 90025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.